Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 1 (January)

1. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
   Genes Chromosomes Cancer, 46(3): 239-47. [Abstract] [Full-text]
2. Immunogenic gangliosides in human ovarian carcinoma.
   Biochem Biophys Res Commun, 353(2): 251-8. [Abstract] [Full-text]
3. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
   J Med Genet, 44(1): 10-15. [Abstract] [Full-text]
4. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
   Cancer Res, 67(1): 326-31. [Abstract] [Full-text]
5. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
   Cancer Res, 67(1): 281-8. [Abstract] [Full-text]
6. Immunohistochemical and ultrastructural analysis of a poorly differentiated pediatric age Sertoli-Leydig cell tumor.
   Exp Mol Pathol, 82(1): 63-7. [Abstract] [Full-text]
7. RNA quality and gene expression analysis of ovarian tumor tissue undergoing repeated thaw-freezing.
   Exp Mol Pathol, 82(1): 95-102. [Abstract] [Full-text]
8. Cancer risks among BRCA1 and BRCA2 mutation carriers.
   Br J Cancer, 96(1): 11-5. [Abstract] [Full-text]
9. A prospective study of postmenopausal hormone use and ovarian cancer risk.
   Br J Cancer, 96(1): 151-6. [Abstract] [Full-text]
10. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Oncogene, 26(2): 198-214. [Abstract] [Full-text]
11. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
    Cancer Chemother Pharmacol, 59(4): 477-84. [Abstract] [Full-text]
12. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
    Cancer, 109(2): 228-38. [Abstract] [Full-text]
13. Development of an ovarian cancer symptom index: possibilities for earlier detection.
    Cancer, 109(2): 221-7. [Abstract] [Full-text]
14. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
    Cancer, 109(2): 332-40. [Abstract] [Full-text]
15. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    J Clin Oncol, 25(3): 301-7. [Abstract] [Full-text]
16. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.
    Cancer Res, 67(2): 585-92. [Abstract] [Full-text]
17. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.
    Br J Cancer, 96(2): 362-72. [Abstract] [Full-text]
18. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Br J Cancer, 96(2): 306-13. [Abstract] [Full-text]
19. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients.
    Br J Cancer, 96(2): 314-20. [Abstract] [Full-text]
20. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation.
    Br J Cancer, 96(2): 296-305. [Abstract] [Full-text]
21. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.
    Br J Cancer, 96(2): 290-5. [Abstract] [Full-text]
22. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p.
    Oncogene, 26(4): 618-32. [Abstract] [Full-text]
23. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases.
    Am J Surg Pathol, 31(2): 255-66. [Abstract] [Full-text]
24. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol, 25(4): 437-43. [Abstract] [Full-text]
25. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.
    J Clin Oncol, 25(4): 384-9. [Abstract] [Full-text]
26. A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.
    BMC Cancer, 7: 14. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.